SCHEMBL5622391

SCHEMBL5622391

CCOC(=O)c1cc2c(F)cccc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.55
ALDH1A1 P00352 5/20 0.55
RAB9A P51151 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
MAPT P10636 4/20 0.55
NPC1 O15118 4/20 0.55
HPGD P15428 3/20 0.55
LMNA P02545 3/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
GLA P06280 1/20 0.55
GAA P10253 1/20 0.55
ATM Q13315 1/20 0.55
HSD17B10 Q99714 1/20 0.52
HRH4 Q9H3N8 2/20 0.52
FLT3 P36888 2/20 0.52
HCRTR1 O43613 1/20 0.50
ALOX15 P16050 1/20 0.50
HTT P42858 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL701020 0.85 KDM4E (0.57) KDM4EALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL913891 0.84 KDM4E (0.56) KDM4EALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL22620711 0.84 KDM4E (0.56) KDM4EALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL2323348 0.84 FLT3 (0.59) MAPTGLAGAAHRH4FLT3
SCHEMBL4044123 0.83 CDK1 (0.57) KDM4EALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL4404148 0.83 KDM4E (0.56) KDM4EALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL5622542 0.83 KDM4E (0.56) KDM4EALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL15904734 0.83 KDM4E (0.55) KDM4EALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL2204502 0.83 KDM4E (0.55) KDM4EALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL6303402 0.83 KDM4E (0.55) KDM4EALDH1A1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2948454-B1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) 2017-05-31 EP claimed
US-9447105-B2 Triazine compounds and a process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-09-20 US claimed
US-20150353566-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-12-10 US claimed
EP-2948454-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) (IN) 2015-12-02 EP claimed
WO-2014115171-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-07-31 WO claimed
CN-109748840-B Synthetic method of 2-substituted indole derivative 中国医学科学院药物研究所 2021-12-07 CN disclosed
EP-2948454-B1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) 2017-05-31 EP disclosed
US-9447105-B2 Triazine compounds and a process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-09-20 US disclosed
US-20150353566-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-12-10 US disclosed
EP-2948454-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) (IN) 2015-12-02 EP disclosed
WO-2014115171-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-07-31 WO disclosed
US-8343981-B2 Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents AICURIS GMBH & CO. KG (DE) 2013-01-01 US disclosed
EP-1003504-B1 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS ASTRAZENECA AB (SE) 2003-07-02 EP disclosed
US-20030119830-A1 Monocyte chemoattractant protein-1 inhibitor compounds ZENECA LIMITED 2003-06-26 US disclosed
US-6573377-B1 Antitumor agent capable of showing its efficacy even against 5- FU drug resistant tumors DAIICHI PHARMACEUTICALS CO., LTD. (JP) 2003-06-03 US disclosed
US-6441004-B1 INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS ZENECA LIMITED (GB) 2002-08-27 US disclosed
CN-1320122-A Pyrazole derivatives and salts thereof DAIICHI SEIYAKU CO (JP) 2001-10-31 CN disclosed
EP-1103551-A1 PYRAZOLE DERIVATIVES AND SALTS THEREOF DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-05-30 EP disclosed
EP-1003504-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS AstraZeneca UK Limited (GB) 2000-05-31 EP disclosed
WO-1999007351-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS ZENECA LIMITED (GB) 1999-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353566-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF TPH2, IDO2, INMT KDM4E 862/4885ALDH1A1 2885/4885RAB9A 4448/4885
US-20030119830-A1 Monocyte chemoattractant protein-1 inhibitor compounds CCL2, CCL11, CCR1 KDM4E 3717/4885ALDH1A1 1888/4885RAB9A 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.